On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Biotech firm Gilead Sciences has announced plans to voluntarily withdraw the US accelerated approval for Trodelvy ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

US drugmakers Gilead Sciences (Nasdaq: GILD) and Merck & Co (NYSE: MRK) have announced new results from a Phase II clinical ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...